Aegopodium Podagraria

by | Apr 16, 2018 | Aegopodium Podagraria

How Can We Help?
You are here:
< Back

Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID).[1] It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.[2] It was also studied in clinical trials for non-small-cell lung cancer.[3] Development was abandoned in 2015 due to poor clinical trial results.[4]

See also

References

  1. ^ "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.
  2. ^ Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
  3. ^ Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al. (January 2015). "Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer". Journal of Clinical Oncology. 33 (2): 189–94. doi:10.1200/JCO.2014.55.5789. PMC 4890680. PMID 25452446.
  4. ^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.
Categories
Table of Contents